Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biomerica (BMRA) Shares Outstanding (Diluted Average) (2019 - 2026)

Biomerica's Shares Outstanding (Diluted Average) history spans 12 years, with the latest figure at $2.9 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 22.56% to $2.9 million in Q1 2026 year-over-year; TTM through Feb 2026 was $2.9 million, a 22.56% increase, with the full-year FY2025 number at $2.3 million, up 9.22% from a year prior.
  • Shares Outstanding (Diluted Average) hit $2.9 million in Q1 2026 for Biomerica, down from $2.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for BMRA hit a ceiling of $16.8 million in Q3 2023 and a floor of $2.1 million in Q2 2024.
  • Historically, Shares Outstanding (Diluted Average) has averaged $8.8 million across 5 years, with a median of $12.7 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): tumbled 87.5% in 2024 and later soared 37.09% in 2025.
  • Tracing BMRA's Shares Outstanding (Diluted Average) over 5 years: stood at $13.5 million in 2022, then increased by 25.02% to $16.8 million in 2023, then tumbled by 87.39% to $2.1 million in 2024, then surged by 37.09% to $2.9 million in 2025, then dropped by 1.93% to $2.9 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for BMRA at $2.9 million in Q1 2026, $2.9 million in Q4 2025, and $2.6 million in Q3 2025.